DavidBrianKarpfMD
Endocrinology • Palo Alto, CADiabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine
Adj. Clinical Professor of Endocrinology, Gerontology & Metabolism Stanford University School of Medicine Attending, Osteoporosis & Metabolic Bone Disease Clinic Stanford University Hospital & Clinics Co-Chair, MSAB American Bone Health, Fellow, ASBMR Senior Endocrine Advisor Spruce Biosciences Senior Endocrine Advisor Calcilytix
Dr. Karpf is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
211 Quarry Rd., 2nd Floor
Palo Alto, CA 94304Phone+1 650-723-6961- Is this information wrong?
Education & Training
UCLA-VA Greater Los AngelesFellowship, Endocrinology, Diabetes, and Metabolism, 1984 - 1985
Cedars-Sinai Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1983 - 1985- Cedars-Sinai Medical CenterResidency, Internal Medicine, 1980 - 1983
University of California San Diego School of MedicineClass of 1980
Certifications & Licensure
CA State Medical License 1981 - 2024
NJ State Medical License 1996 - 1997- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Fellow ASBMR, 2020
- NIH FIRST Award NIH, 1991
- Merit Review Award, VAMC-SF VA, 1989
- Join now to see all
Clinical Trials
- A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Start of enrollment: 2016 Dec 13
- A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency Start of enrollment: 2017 Nov 13
- A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial Start of enrollment: 2017 Dec 19
- Join now to see all
Publications & Presentations
PubMed
- Response to Letter to the Editor From Malozowski: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial".Paul S Thornton, Aristides K Maniatis, Elena Aghajanova, Elena Chertok, Zhengning Lin, Wenjie Song, Eva Dam Christoffersen, Vibeke Miller Breinholt, Elene Giorgadze, M...> ;The Journal of Clinical Endocrinology and Metabolism. 2022 Apr 19
- Response to Letter to the Editor From L. Sävendahl et al: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial".Paul S Thornton, Aristides K Maniatis, Elena Aghajanova, Elena Chertok, Elpis Vlachopapadopoulou, Zhengning Lin, Wenjie Song, Eva Dam Christoffersen, Vibeke Miller Bre...> ;The Journal of Clinical Endocrinology and Metabolism. 2022 Feb 17
- 25 citationsWeekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial.Paul S. Thornton, Aristides K Maniatis, Elena Aghajanova, Elena Chertok, Elpis Vlachopapadopoulou, Zhengning Lin, Wenjie Song, Eva Dam Christoffersen, Vibeke Miller Br...> ;The Journal of Clinical Endocrinology and Metabolism. 2021 Oct 21
- Join now to see all
Press Mentions
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical UpdatesMay 3rd, 2023- CEO Update: Interview with Lumos Pharma's Chief Medical Officer, David B. Karpf, M.D.July 26th, 2022
- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
